%0 Journal Article %1 Kloft.2006 %A Kloft, Charlotte %A Wallin, Johan %A Henningsson, Anja %A Chatelut, Etienne %A Karlsson, Mats O. %D 2006 %J Clin Cancer Res %K imported %N 18 %P 5481-5490 %T Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs %V 12 %X Purpose: Cancer chemotherapy, although based on body surface area, often causes unpredictable myelosuppression, especially severe neutropenia. The aim of this study was to evaluate qualitatively and quantitatively the influence of patient-specific characteristics on the neutrophil concentration-time course, to identify patient subgroups, and to compare covariates on system-related pharmacodynamic variable between drugs. Experimental Design: Drug and neutrophil concentration, demographic, and clinical chemistry data of several trials with docetaxel (637 patients), paclitaxel (45 patients), etoposide (71 patients), or topotecan (191 patients) were included in the covariate analysis of a physiology-based pharmacokinetic-pharmacodynamic neutropenia model. Comparisons of covariate relations across drugs were made. Results: A population model incorporating four to five relevant patient factors for each drug to explain variability in the degree and duration of neutropenia has been developed.

@article{Kloft.2006, abstract = {Purpose: Cancer chemotherapy, although based on body surface area, often causes unpredictable myelosuppression, especially severe neutropenia. The aim of this study was to evaluate qualitatively and quantitatively the influence of patient-specific characteristics on the neutrophil concentration-time course, to identify patient subgroups, and to compare covariates on system-related pharmacodynamic variable between drugs. Experimental Design: Drug and neutrophil concentration, demographic, and clinical chemistry data of several trials with docetaxel (637 patients), paclitaxel (45 patients), etoposide (71 patients), or topotecan (191 patients) were included in the covariate analysis of a physiology-based pharmacokinetic-pharmacodynamic neutropenia model. Comparisons of covariate relations across drugs were made. Results: A population model incorporating four to five relevant patient factors for each drug to explain variability in the degree and duration of neutropenia has been developed. }, added-at = {2010-02-04T16:31:48.000+0100}, author = {Kloft, Charlotte and Wallin, Johan and Henningsson, Anja and Chatelut, Etienne and Karlsson, Mats O.}, biburl = {https://www.bibsonomy.org/bibtex/2a12087a75d7c1ae28ac04d1cf664ec44/hruehs}, interhash = {d7fc95747a7ec21946aebaf830f49a47}, intrahash = {a12087a75d7c1ae28ac04d1cf664ec44}, journal = {Clin Cancer Res}, keywords = {imported}, number = 18, pages = {5481-5490}, timestamp = {2010-02-04T16:31:52.000+0100}, title = {Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs}, volume = 12, year = 2006 }